Immunex Overview
- Year Founded
-
1981
- Status
-
Acquired/Merged
- Employees
-
1,618
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$17.8B
Immunex General Information
Description
Operator of a biopharmaceutical company intended to manufacture, develop and market therapeutic products. The company's therapeutic products were essentially immune system proteins that acted as hormones in the body enabling it to offer treatments for cancer, infectious diseases and autoimmune disorders.
Contact Information
Website
www.immunex.comCorporate Office
- 51 University Street
- Seattle, WA 98101
- United States
Corporate Office
- 51 University Street
- Seattle, WA 98101
- United States
Immunex Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 15-Jul-2002 | $17.8B | Completed | Generating Revenue | ||
| 4. 2PO | 13-Nov-2000 | Completed | Generating Revenue | |||
| 3. Convertible Debt | 20-May-1999 | Completed | Generating Revenue | |||
| 2. IPO | 01-Jul-1983 | $6M | Completed | Generating Revenue | ||
| 1. Early Stage VC | 01-Jul-1982 | $6M | $6M | Completed | Generating Revenue |
Immunex Patents
Immunex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2009140469-A3 | Dosage regimen comprising ap02l/trail, anti-vegf / anti-cd20 and chemotherapy to treat nsclc or non-hodgkin's lymphoma, respectively | Inactive | 14-May-2008 | ||
| WO-2009140469-A2 | Methods of using apo2l/trail to treat cancer | Inactive | 14-May-2008 | ||
| CA-2583677-A1 | Tnf-like weak inducer of apoptosis (tweak) receptor binding domain | Inactive | 22-Oct-2004 | ||
| AU-2005299919-A1 | Tweak receptor | Active | 22-Oct-2004 | ||
| AU-2005299919-B2 | Tweak receptor | Inactive | 22-Oct-2004 | A61K39/3955 |
Immunex Signals
Immunex Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cable & Howse Ventures | Venture Capital | Minority | ||
| Domain Associates | Venture Capital | Minority | ||
| Eurand | Corporation | Minority | ||
| Mayfield Fund | Venture Capital | Minority | ||
| New Enterprise Associates | Venture Capital | Minority |
Immunex FAQs
-
When was Immunex founded?
Immunex was founded in 1981.
-
Where is Immunex headquartered?
Immunex is headquartered in Seattle, WA.
-
What is the size of Immunex?
Immunex has 1,618 total employees.
-
What industry is Immunex in?
Immunex’s primary industry is Biotechnology.
-
Is Immunex a private or public company?
Immunex is a Private company.
-
What is the current valuation of Immunex?
The current valuation of Immunex is .
-
What is Immunex’s current revenue?
The current revenue for Immunex is .
-
How much funding has Immunex raised over time?
Immunex has raised $3.24B.
-
Who are Immunex’s investors?
Cable & Howse Ventures, Domain Associates, Eurand, Mayfield Fund, and New Enterprise Associates have invested in Immunex.
-
When was Immunex acquired?
Immunex was acquired on 15-Jul-2002.
-
Who acquired Immunex?
Immunex was acquired by Amgen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process